Exelixis (EXEL) Other Non-Current Assets (2010 - 2022)
Exelixis (EXEL) posted quarterly Other Non-Current Assets of $280.0 million for Q3 2022, up 107.91% year-over-year from $134.7 million in Q3 2021, and little changed quarter-over-quarter from $279.7 million in Q3 2022.
Exelixis (EXEL) Other Non-Current Assets (2010 - 2022) Analysis & Trends
Exelixis' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $280.0 million for Q3 2022.
- In Q3 2022, Other Non-Current Assets rose 107.91% year-over-year to $280.0 million; the TTM figure through Sep 2022 stood at $280.0 million (up 107.91% YoY), while the FY2021 annual figure was $131.0 million, up 78.46% from the prior year.
- Other Non-Current Assets for Q3 2022 stood at $280.0 million, roughly flat from $279.7 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $280.0 million in Q3 2022, with the low at $1.1 million in Q2 2018.
- The 5-year median for Other Non-Current Assets is $60.5 million (2020), against an average of $82.3 million.
- The sharpest annual moves came in 2019 and 2020: Other Non-Current Assets dropped 26.67% in 2019, then surged 5110.18% in 2020.
- Exelixis' Other Non-Current Assets stood at $8.3 million in 2018, then fell by 12.34% to $7.3 million in 2019, then soared by 854.99% to $69.4 million in 2020, then jumped by 88.74% to $131.0 million in 2021, then soared by 113.74% to $280.0 million in 2022.
- Business Quant data shows EXEL's Other Non-Current Assets at $280.0 million in Q3 2022, $279.7 million in Q3 2022, and $139.0 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 280.01 Mn |
| Jul 1, 2022 | 279.71 Mn |
| Apr 1, 2022 | 138.99 Mn |
| Dec 31, 2021 | 131.00 Mn |
| Oct 1, 2021 | 134.68 Mn |
| Jul 2, 2021 | 134.93 Mn |
| Apr 2, 2021 | 124.68 Mn |
| Jan 1, 2021 | 73.41 Mn |
| Oct 2, 2020 | 69.41 Mn |
| Jul 3, 2020 | 60.50 Mn |
| Apr 3, 2020 | 57.31 Mn |
| Jan 3, 2020 | 53.15 Mn |
| Sep 27, 2019 | 7.27 Mn |
| Jun 28, 2019 | 5.76 Mn |
| Mar 29, 2019 | 1.10 Mn |
| Dec 28, 2018 | 8.29 Mn |
| Sep 28, 2018 | 1.10 Mn |
| Jun 29, 2018 | 1.10 Mn |
| Mar 30, 2018 | 1.50 Mn |
| Dec 29, 2017 | 4.65 Mn |